In Travenol's licence application for Hemofil the appendix includes a warning that the concentrate should be used when its expected effect is needed in spite of the unknown hepatitis risk associated with its use and special consideration should be given to the use of the concentrate in newborns and infants where a higher morbidity and mortality may be associated with hepatitis.